References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailApplying a simple clinical tool to identify osteoporosis among Japanese women
Fujiwara, S; Masunari, N; Suzuki, G et al

in BONE (2001), S28

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate increases cartilage matrix formation
Henrotin, Yves ULg; Labasse, A; Galais, P et al

in BONE (2001), S28

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailDevelopment of a predictive model and a risk assessment instrument to facilitate diagnosis of low bone mass in postmenopausal women
Ben Sedrine, Wafa ULg; Chevalier, Th; Micheletti, MC et al

in Arthritis and Rheumatism (2001), 44(1570), 314

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailKorean experience with OSTA risk index for osteoporosis : a validation study
Ben Sedrine, Wafa ULg; Park, HM; Reginster, Jean-Yves ULg

in Arthritis and Rheumatism (2001), 44(1246), 260

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailUsing the OSTA index to identify women at risk of osteoporosis : a validation study in China
Ben Sedrine, Wafa ULg; Huang, Q; Reginster, Jean-Yves ULg

in Arthritis and Rheumatism (2001), 44(1233), 258

Detailed reference viewed: 27 (1 ULg)
Full Text
Peer Reviewed
See detailA simple table based on age and weight identifies Asian women at risk of osteoporosis
Ben Sedrine, Wafa ULg; Lin Liu, G; Reginster, Jean-Yves ULg

in Arthritis and Rheumatism (2001), 44(1232), 258

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailValidation of the OSTA risk index in Japanese women
Ben Sedrine, Wafa ULg; Fujiwara, S; Masunari, N et al

in Arthritis and Rheumatism (2001), 44(1231), 258

Detailed reference viewed: 28 (0 ULg)
Peer Reviewed
See detailSecular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy.
Reginster, Jean-Yves ULg; Gillet, Pierre ULg; Gosset, Christiane ULg

in Bulletin of the World Health Organization (2001), 79(10), 942-6

OBJECTIVE: To determine the incidence of hip fractures (at the proximal end of the femur) in Belgium from 1984 to 1996. METHODS: Use was made of information from the national database on hospital bills ... [more ▼]

OBJECTIVE: To determine the incidence of hip fractures (at the proximal end of the femur) in Belgium from 1984 to 1996. METHODS: Use was made of information from the national database on hospital bills, which fully covers the annual hospital stays in the whole of the country. FINDINGS: The mean annual incidence of hip fractures increased from 107.8 to 140.5 per 100,000 inhabitants between 1984 and 1996. The incidence of fractures of the femoral shaft (diaphysis), taken as a control, remained stable. The female to male ratio of these hip fractures was 2.3:1. Although the incidence by age group was identical for males and females, the fractures occurred approximately seven years earlier in women than in men. The demographic changes observed in Belgium during this period accounted for only 10% of the observed increase in the number of hip fractures. CONCLUSION: If no comprehensive preventive policy is set up promptly, there will be a sevenfold increase in the incidence of hip fractures between now and the year 2050 in Belgium. [less ▲]

Detailed reference viewed: 16 (9 ULg)
Full Text
Peer Reviewed
See detailRecommandations for the registration of drugs used in the treatment of osteoarthritis : an update on biochemical markers
Vignon, E; Gamero, P; Delmas, P et al

in Osteoarthritis and Cartilage (2001), 9

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailCorrect regimen of fluoride and calcium reduces the risk of vertebral fractures in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Rovati, L; Setnikar, I

in Osteoporosis International (2001), 12

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailSymptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study.
Appelboom, T; Schuermans, J; Verbruggen, G et al

in Scandinavian Journal of Rheumatology (2001), 30(4), 242-7

OBJECTIVES: We compare the symptomatic effects of 300 or 600mg daily of ASU in patients with knee osteoarthritis. METHODS: A multicenter, double blind, study comparing a daily intake of 300mg or 600mg of ... [more ▼]

OBJECTIVES: We compare the symptomatic effects of 300 or 600mg daily of ASU in patients with knee osteoarthritis. METHODS: A multicenter, double blind, study comparing a daily intake of 300mg or 600mg of ASU and placebo. The study lasted 3 months and involved patients of both genders, aged 45 to 80 years and presenting with femoro-tibial knee osteoarthritis. The primary endpoint was NSAIDs and analgesics intake between D30 and D90. RESULTS: All efficacy parameters were significantly improved (p<0.01), in the two ASU groups compared to the placebo group. At D90, NSAIDs and analgesics intake decreased by more than 50% in 71% of the patients receiving ASU 300mg or 600mg, compared to 36% of the patients receiving placebo. From DO to D90 Lequesne's index dropped by 3.9 and 2.9 points in ASU 300mg and 600mg groups, respectively, against 1.6 in those receiving placebo. CONCLUSION: The efficacy of ASU at a dosage of 300mg/day and 600mg/day was consistently superior to that of placebo at all endpoints, with no differences observed between the two doses. [less ▲]

Detailed reference viewed: 47 (5 ULg)
Full Text
Peer Reviewed
See detailA simple tool to identify asian women at increased risk of osteoporosis.
Koh, L K; Sedrine, W B; Torralba, T P et al

in Osteoporosis International (2001), 12(8), 699-705

Patients with low bone mineral density (BMD) have a high risk of future fractures, and should be actively considered for treatment to reduce their risk. However, BMD measurements are not widely available ... [more ▼]

Patients with low bone mineral density (BMD) have a high risk of future fractures, and should be actively considered for treatment to reduce their risk. However, BMD measurements are not widely available in some communities, because of cost and lack of equipment. Simple questionnaires have been designed to help target high-risk women for BMD measurements, thereby avoiding the cost of measuring women at low risk. However, such tools have previously focused on evaluation of non-Asian women. We collected information about numerous risk factors from postmenopausal Asian women in eight countries in Asia using questionnaires, and evaluated the ability of these risk factors to identify women with osteoporosis as defined by femoral neck BMD T-scores < or =-2.5. Multiple variable regression analysis and item reduction yielded a final tool based on only age and body weight. This risk index had a sensitivity of 91% and specificity of 45%, with an area under the curve of 0.79. Previously published risk indices based on larger numbers of variables performed similarly well in this Asian population. Large differences in risk were identified using our index to create three categories: 61% of the high-risk women had osteoporosis, compared with only 15% and 3% of the intermediate- and low-risk women, respectively. The low-risk group represented 40% of all women, for whom BMD measurements are probably not needed unless important risk factors, such as prior nonviolent fracture or corticosteroid use, are present. An existing population-based sample of postmenopausal Japanese women was used to validate our index. In this sample of Japanese women the sensitivity was 98% and specificity was 29%; the low-risk category, for whom BMD is probably unnecessary, represented 25% of all women. We conclude that our index performed well for classifying the risk of osteoporosis among postmenopausal Asian women and applying it would result in more prudent use of BMD technology. [less ▲]

Detailed reference viewed: 23 (4 ULg)
Full Text
Peer Reviewed
See detailEffect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer, R M; Arnaud, C D; Zanchetta, J R et al

in New England Journal of Medicine [=NEJM] (2001), 344(19), 1434-41

BACKGROUND: Once-daily injections of parathyroid hormone or its amino-terminal fragments increase bone formation and bone mass without causing hypercalcemia, but their effects on fractures are unknown ... [more ▼]

BACKGROUND: Once-daily injections of parathyroid hormone or its amino-terminal fragments increase bone formation and bone mass without causing hypercalcemia, but their effects on fractures are unknown. METHODS: We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observation, 21 months) and performed serial measurements of bone mass by dual-energy x-ray absorptiometry. RESULTS: New vertebral fractures occurred in 14 percent of the women in the placebo group and in 5 percent and 4 percent, respectively, of the women in the 20-microg and 40-microg parathyroid hormone groups; the respective relative risks of fracture in the 20-microg and 40-microg groups, as compared with the placebo group, were 0.35 and 0.31 (95 percent confidence intervals, 0.22 to 0.55 and 0.19 to 0.50). New nonvertebral fragility fractures occurred in 6 percent of the women in the placebo group and in 3 percent of those in each parathyroid hormone group (relative risk, 0.47 and 0.46, respectively [95 percent confidence intervals, 0.25 to 0.88 and 0.25 to 0.861). As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the radius by 2 more percentage points. Both doses increased total-body bone mineral by 2 to 4 more percentage points than did placebo. Parathyroid hormone had only minor side effects (occasional nausea and headache). CONCLUSIONS: Treatment of postmenopausal osteoporosis with parathyroid hormone (1-34) decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated. The 40-microg dose increased bone mineral density more than the 20-microg dose but had similar effects on the risk of fracture and was more likely to have side effects. [less ▲]

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailGenetics of menopause-associated diseases.
Massart, François ULg; REGINSTER, Jean-Yves ULg; Brandi, M L

in Maturitas (2001), 40(2), 103-16

Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is estimated that perhaps 50 million women worldwide will go into menopause annually ... [more ▼]

Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is estimated that perhaps 50 million women worldwide will go into menopause annually. Atherosclerotic cardiovascular disease, osteoporotic fractures and Alzheimer's dementia are common chronic disorders after menopause, representing major health problems in most developed countries. Apart from being influenced by environmental factors, these chronic disorders recognize a strong genetic component, and there are now considerable clinic evidences that these disorders are related to low hormonal milieu of postmenopausal women. Here, we review up-to-date available data suggesting that genetic variation may contribute to higher susceptibility to four sporadic chronic syndromes such as osteoporosis (OP), osteoarthritis (OA), Alzheimer's disease (AD) and coronary artery disease (CAD). For these four syndromes candidate genes that today appear as major loci in genetic susceptibility encode for proteins specific of a given system, as the vitamin D receptor (VDR) gene for the skeleton and, therefore, OP or angiotensin converting enzyme (ACE) for the cardiovascular system and, therefore, CAD. The investigation of gene polymorphisms in various pathological conditions typical of postmenopause offer an explanation not only of their genetic inheritance but also of their co-segregation in given individuals. In this view, it may be possible to identify a common set of genes whose variants contribute to a common genetic background for these different disorders. Ideal candidates appear genes of the estrogen response cascade [i.e. estrogen receptor (ERs), enzymes involved in estrogen metabolism or co-activators and co-inhibitors]. All together this information may represent the basis both for future recognition of individuals at risk and for the pharmacogenetic driving of drug responsiveness. [less ▲]

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailIpriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Alexandersen, P; Toussaint, André ULg; Christiansen, C et al

in JAMA : Journal of the American Medical Association (2001), 285(11), 1482-8

CONTEXT: Data on the efficacy and safety of ipriflavone for prevention of postmenopausal bone loss are conflicting. OBJECTIVES: To investigate the effect of oral ipriflavone on prevention of ... [more ▼]

CONTEXT: Data on the efficacy and safety of ipriflavone for prevention of postmenopausal bone loss are conflicting. OBJECTIVES: To investigate the effect of oral ipriflavone on prevention of postmenopausal bone loss and to assess the safety profile of long-term treatment with ipriflavone in postmenopausal osteoporotic women. DESIGN AND SETTING: Prospective, randomized, double-blind, placebo-controlled, 4-year study conducted in 4 centers in Belgium, Denmark, and Italy from August 1994 to July 1998. PARTICIPANTS: Four hundred seventy-four postmenopausal white women, aged 45 to 75 years, with bone mineral densities (BMDs) of less than 0.86 g/cm(2). INTERVENTIONS: Patients were randomly assigned to receive ipriflavone, 200 mg 3 times per day (n = 234), or placebo (n = 240); all received 500 mg/d of calcium. MAIN OUTCOME MEASURES: Efficacy measures included spine, hip, and forearm BMD and biochemical markers of bone resorption (urinary hydroxyproline corrected for creatinine and urinary CrossLaps [Osteometer Biotech, Herlev, Denmark] corrected for creatinine), assessed every 6 months. Laboratory safety measures and adverse events were recorded every 3 months. RESULTS: Based on intent-to-treat analysis, after 36 months of treatment, the annual percentage change from baseline in BMD of the lumbar spine for ipriflavone vs placebo (0.1% [95% confidence interval (CI), -7.9% to 8.1%] vs 0.8% [95% CI, -9.1% to 10.7%]; P =.14), or in any of the other sites measured, did not differ significantly between groups. The response in biochemical markers was also similar between groups (eg, for hydroxyproline corrected for creatinine, 20.13 mg/g [95% CI, 18.85-21.41 mg/g] vs 20.67 mg/g [95% CI, 19.41-21.92 mg/g]; P =.96); urinary CrossLaps corrected for creatinine, 268 mg/mol (95% CI, 249-288 mg/mol) vs 268 mg/mol (95% CI, 254-282 mg/mol); P =.81. The number of women with new vertebral fracture was identical or nearly so in the 2 groups at all time points. Lymphocyte concentrations decreased significantly (500/microL (0.5 x 10(9)/L]) in women treated with ipriflavone. Thirty-one women (13.2%) in the ipriflavone group developed subclinical lymphocytopenia, of whom 29 developed it during ipriflavone treatment. Of these, 15 (52%) of 29 had recovered spontaneously by 1 year and 22 (81%) of 29 by 2 years. CONCLUSIONS: Our data indicate that ipriflavone does not prevent bone loss or affect biochemical markers of bone metabolism. Additionally, ipriflavone induces lymphocytopenia in a significant number of women. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailA comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine.
Valat, J P; Accardo, S; REGINSTER, Jean-Yves ULg et al

in Inflammation Research (2001), 50(Suppl 1), 30-4

OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of meloxicam compared with diclofenac in patients with osteoarthritis of the lumbar spine. SUBJECTS: 229 patients with ... [more ▼]

OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of meloxicam compared with diclofenac in patients with osteoarthritis of the lumbar spine. SUBJECTS: 229 patients with radiologically confirmed osteoarthritis of the lumbar spine. TREATMENT AND METHODS: Once-daily meloxicam 7.5 mg tablet or diclofenac 100 mg slow release tablet. Efficacy and tolerability parameters were assessed at baseline and after 3, 7 and 14 days of treatment. RESULTS: The two drugs had equal short-term efficacy, with pain on motion of lumbar spine significantly (p<0.05) decreased at Day 3. Secondary efficacy variables were also significantly improved at Days 3, 7 and 14. There were no statistically significant differences between the two drugs, although the global tolerability of meloxicam was significantly better than for diclofenac, as assessed by the investigators (p = 0.0072) and the patients (p = 0.049). CONCLUSIONS: Meloxicam and diclofenac were equivalent in relieving the acute pain associated with osteoarthritis of the lumbar spine. However, meloxicam was much better tolerated. [less ▲]

Detailed reference viewed: 27 (3 ULg)